CPTx
CPTx develops single-stranded DNA payloads with nonviral LNP delivery for in vivo CAR-T. The company reports small-animal validation; durability, redosing, and immune-silence statements remain company claims. CPTx is a distinct company from Capstan and the CPTX2309 drug code.
Corporate information
- Company entity
- CPTx
- Headquarters / principal office
- Planegg, Germany; additional office in South San Francisco, California ↗
- Founded
- 2021 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://cptx.bio/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
CPTx develops single-stranded DNA payloads with nonviral LNP delivery for in vivo CAR-T. The company reports small-animal validation; durability, redosing, and immune-silence statements remain company claims. CPTx is a distinct company from Capstan and the CPTX2309 drug code.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- CPTx — official page checked November 4, 2026
- CPTx — official company history
- CPTx financing disclosure — conflicting title/body amounts